ReviewJournal of advanced research2026
Circular RNA-mediated regulation of key signaling pathways in cardiovascular diseases: a review.
Review in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- CircRNA-regulated programmed cell death networks in cardiomyocytes: Molecular crosstalk and therapeutic translation.Non-coding RNA research · 2026Review
- Circular RNA circAHSA1 serves as a stable serum biomarker for the diagnosis and progression of gastric cancer.Translational oncology · 2026Article
- Non-coding RNAs in heart failure: epigenetic regulatory mechanisms and therapeutic potential.Frontiers in genetics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) are globally prevalent pathologies driven by dysregulated signaling networks. Circular RNAs (circRNAs), a class of covalently closed non-coding RNAs produced by back-splicingmechanism, in which a downstream 5' splice site joins an upstream 3' splice site, have emerged as critical regulators of CVD pathogenesis. This review examines their lifecycle, including biogenesis, nuclear export mechanisms, subcellular localization, and degradation, along with their functional roles in microRNA sequestration, protein interactions, transcriptional regulation, and polypeptide translation. Recent advances in circRNA engineering are also discussed, including in vitro synthesis strategies, delivery platforms, vaccine development, gene editing, and aptamers (synthetic high-affinity nucleic acid ligands).Furthermore, we explore the latest findings that focus on how circRNAs modulate these core CVD-related pathways. The unique expression patterns and engineering potential of circRNAs render them valuable candidates for biomarker and therapy development. This review connects the fundamental biology of circRNAs to recent technological advances, offering a roadmap for leveraging the functional interaction between circRNAs and signaling pathways in CVD precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.